Hvidovre Hospital

Hvidovre, Denmark

Hvidovre Hospital

Hvidovre, Denmark
SEARCH FILTERS
Time filter
Source Type

Patent
Hvidovre Hospital | Date: 2017-05-24

The present disclosure relates to ascoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane. The disclosure furthermore relates to a method for manufacturing a scoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane and a method for reducing risk and/or treating spinal deformities, such as scoliosis, of a patient by applying pressure to the thoracic spine of the patient, such that the thoracic spine of the patient is bent forward in the sagittal plane.


The present invention relates to methods for obtaining a whole virus vaccine candidate stock. The present invention also relates to an inactivated whole virus vaccine candidate stock that can be used for vaccination purposes as well as development of novel high titer virus, which is the preferred virus for this technique.


Patent
Hvidovre Hospital | Date: 2015-07-10

The present disclosure relates to ascoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane. The disclosure furthermore relates to a method for manufacturing a scoliosis monopiece plate, to fit tightly on the back of a user, comprising a lower section and an upper section, wherein the upper section is rounded in the sagittal plane, such that the plate is configured to force the thoracic spine of the user to bend forward in the sagittal plane and a method for reducing risk and/or treating spinal deformities, such as scoliosis, of a patient by applying pressure to the thoracic spine of the patient, such that the thoracic spine of the patient is bent forward in the sagittal plane.


"We have successfully completed this key clinical milestone in the launch of our Nu.QTM Triage product. This study, with the total cohort totalling just under 8000 subjects demonstrates that the Nu.QTM  Triage test was able to prevent 24.5% of colonoscopies and detect almost 95% of colorectal cancers and 87.9% of high-risk adenomas. It further strengthens the case for the Nu.QTM Colorectal Cancer Screening Triage test to be incorporated into colorectal cancer screening programs," said Louise Day, Chief Marketing and Communications Officer at Volition. Professor Hans Jorgen Nielsen from Hvidovre Hospital, University of Copenhagen, commented, "These results, from a very large data set, confirm that the Nu.QTM Triage test has the potential to accelerate the diagnosis of colorectal cancer, by reducing the number of unnecessary colonoscopies being performed thereby allowing more people to be screened quickly and effectively." The presentation from the DDW can be found and downloaded at www.volitionrx.com Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide. For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via: The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only. Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-final-results-from-8000-patient-clinical-trial-in-denmark-to-evaluate-the-performance-of-its-nuqtm-triage-test-300454011.html


New data confirms prior test results that Volition's novel blood test can accurately detect colorectal cancer and reduce colonoscopies NAMUR, Belgium, May 9, 2017 /PRNewswire/ -- At the Digestive Disease Week 2017 (DDW) in Chicago, VolitionRx Limited (NYSE MKT: VNRX) presented results that continue to show that the Nu.QTM Colorectal Cancer Screening Triage Test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection. "We have successfully completed this key clinical milestone in the launch of our Nu.QTM Triage product. This study, with the total cohort totalling just under 8000 subjects demonstrates that the Nu.QTM  Triage test was able to prevent 24.5% of colonoscopies and detect almost 95% of colorectal cancers and 87.9% of high-risk adenomas. It further strengthens the case for the Nu.QTM Colorectal Cancer Screening Triage test to be incorporated into colorectal cancer screening programs," said Louise Day, Chief Marketing and Communications Officer at Volition. Professor Hans Jorgen Nielsen from Hvidovre Hospital, University of Copenhagen, commented, "These results, from a very large data set, confirm that the Nu.QTM Triage test has the potential to accelerate the diagnosis of colorectal cancer, by reducing the number of unnecessary colonoscopies being performed thereby allowing more people to be screened quickly and effectively." The presentation from the DDW can be found and downloaded at www.volitionrx.com Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide. For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via: The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only. Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-final-results-from-8000-patient-clinical-trial-in-denmark-to-evaluate-the-performance-of-its-nuqtm-triage-test-300454011.html


Pachler J.,Hvidovre Hospital
Cochrane database of systematic reviews (Online) | Year: 2012

For almost one hundred years abdominoperineal excision has been the standard treatment of choice for rectal cancer. With advances in the techniques for rectal resection and anastomosis, anterior resection with preservation of the sphincter function has become the preferred treatment for rectal cancers, except for those cancers very close to the anal sphincter. The main reason for this has been the conviction that the quality of life for patients with a colostomy after abdominoperineal excision was poorer than for patients undergoing an operation with a sphincter-preserving technique. However, patients having sphincter-preserving operations may experience symptoms affecting their quality of life that are different from stoma-patients. To compare the quality of life in rectal cancer patients with or without permanent colostomy. We searched PUBMED, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Colorectal Cancer Group's specialised register. Abstract books from major gastroenterological and colorectal congresses were searched. Reference lists of the selected articles were scrutinized. All controlled clinical trials and observational studies in which quality of life was measured in patients with rectal cancer having either abdominoperineal excision/Hartmann's operation or low anterior resection, using a validated quality of life instrument, were considered. One reviewer (JP) checked the titles and abstracts identified from the databases and hand search. Full text copies of all studies of possible relevance were obtained. The reviewer decided which studies met the inclusion criteria. Both reviewers independently extracted data. If information was insufficient the original author was contacted to obtain missing data. Extracted data were cross-checked and discrepancies resolved by consensus. Sixty-nine potential studies were identified. Thirty-five of these, all non-randomised and representing 5127 participants met the inclusion criteria. Fourteen trials found that people undergoing abdominoperineal excision/Hartmann's operation did not have poorer quality of life measures than patients undergoing anterior resection. The rest of the studies found some difference, but not always in favour of non-stoma patients. Due to clinical heterogeneity and the fact that all studies were observational trials, meta-analysis of the included studies was not possible. The studies included in this review do not allow firm conclusions as to the question of whether the quality of life of people after anterior resection is superior to that of people after abdominoperineal excision/Hartmann's operation. The included studies challenges the assumption that anterior resection patients fare better. Larger, better designed and executed prospective studies are needed to answer this question.


Patent
Hvidovre Hospital | Date: 2014-06-23

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.


Patent
Hvidovre Hospital and United States Of America As Represented By The Secretary | Date: 2014-10-14

The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.


The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) of genotype 2b that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs, which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.


Patent
Hvidovre Hospital | Date: 2014-10-21

The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.

Loading Hvidovre Hospital collaborators
Loading Hvidovre Hospital collaborators